F-star Therapeutics, Inc. (NasdaqCM: FSTX) Loss Submission Form

Kuznicki Law is investigating the proposed sale of F-star Therapeutics, Inc. (NasdaqCM: FSTX) to invoX Pharma.  Under the terms of the proposed transaction, shareholders of F-star will receive only $7.12 in cash for each share of F-star that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.